410 Non-Invasive Diagnosis of Prostate Cancer from Body Fluids Using a Panel of Tumor Suppressor Genes (original) (raw)

Eur Urol Suppl 2011;10(2):143 results: The median of follow-up was 42.9 months (27.14-49.5). Patients with MPC had significantly higher CTC levels [m: 18.5 (1-126)] compared with the other two groups (P < 0.001). A significant positive correlation was demonstrated (P < 0.001) between CTC levels and all tumour burden markers: PSA (Rho = 0.55), T (Tau = 0.47), N (m N1: 18.5, m N0: 0.0) and M ( Tau = 0.54) except Gleason score(Tau = 0.16). The overall survival to 6, 12 and 18 months was 80 %, 69 % and 62 % respectively. The progression-free survival to 6, 12 and 18 months was 76 %, 46 % and 33 % respectively. A cut-off level ≥ 4 CTC (S: 90 %; E: 87.6 %) was chosen to distinguish patients with an unfavorable prognosis. These patients had a significantly shorter median overall and progression-free survival (P < 0.001). As the CTC levels were increasing, the overall survival and progression-free survival decreased. The risk of mortality and progression for the patients with ≥ 4 CTC was 4.1 (IC 95 %: 1.1-14.6; P = 0.029) and 8.5 (IC 95 %: 2.6-26.9; P < 0.001) times higher. Using a multivariate piecewise Cox regression mode, the level of ≥ 4 CTC was an independent predictor of PSA relapse (HR: 5,9; IC 95 %: 1,(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)4; p <0,005). Conclusions: The immunomagnetic analysis allows us to quantify the CTC in peripheral blood and could provide a possibility for correctly staging and to estimate the prognostic value of the metastatic hormone-sensitive prostate cancer with the purpose of the early onset of new therapies.